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Abstract: Sphingosine-1-phosphate (S1P) is a sphingolipid metabolite with many important functions 
in cellular and systemic physiology, including the immune system. As it cannot traverse the membrane, 
it is exported from cells by transporters. Several members of the ATP-binding cassette (ABC) 
transporter family, ABCA1, ABCC1, ABCG2 and potentially ABCA7 have been identified as S1P 
transporters. In addition spinster 2 (SPNS2), a protein from the major facilitator superfamily (MFS), 
was identified as a S1P transporter. Here we review the current knowledge on S1P transport and 
discuss how this process creates S1P gradients in the body that are important in various functions of the 
immune system. 
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ABC = ATP-binding cassette; CDase = ceramidase; DC = dendritic cell; HEV = high endothelial 
venule; MFS = major facilitator superfamily; NET = neutrophil extracellular trap; PRR = 
pattern-recognition receptor; SMase = sphingomyelinase; S1P = sphingosine-1-phosphate; S1PR = 
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1. Transport of S1P 
Local production and export of sphingosine-1-phosphate (S1P) can generate concentration 
gradients of this bioactive sphingolipid in the body [1,2]. Given the potential role for S1P transporters 
in establishing such gradients, it is important to identify the molecular nature of these transporters. 
Both ATP-binding cassette (ABC) transporters and spinster 2 (SPNS2) have been revealed as 
transporters able to move S1P over the cell membrane. 
1.1. ABC transporter-mediated transport of S1P 
The family of ABC transporters is an important group of membrane-associated proteins that serve 
as transmembrane transporters for various substrates, such as lipids, cytokines and cytostatics. Of the 
48 human ABC transporters almost half are thought to translocate lipids or lipid-related compounds, 
including phospholipids, cholesterol and sphingolipids [3]. S1P is an important sphingolipid 
metabolite with well-established signaling functions. It is generated in the sphingolipid catabolic 
pathway by phosphorylation of sphingosine through the action of either of two sphingosine kinases 
(SphK), SphK1 and SphK2, of which SphK1 acts at the plasma membrane (Figure 1A) [4]. 
Sphingomyelin (SM) is a source for generation of S1P in the plasma membrane and is initially 
converted to sphingosine by the subsequent actions of the enzymes sphingomyelinase (SMase), which 
generates ceramide, and ceramidase (CDase; Figure 1A). SM is considered to localize in the 
exoplasmic leaflet of the plasma membrane and is not prone to flipping to the cytoplasmic leaflet. Both 
SMase and CDase act on the exoplasmic leaflet and together generate sphingosine [5,6]. Sphingosine 
therefore has to flip to the cytoplasmic leaflet of the plasma membrane to allow SphK1 to convert it 
into S1P. Catabolism of S1P inside the cell by S1P lyase (SPL) leads to the formation of hexadecenal 
and phosphoethanolamine [7]. Alternatively, S1P is dephosphorylated to sphingosine, for which 
several phosphatases are known to exist [8]. So, at least 5 enzymes together determine the 
(intra)cellular levels of S1P (Figure 1A). 
Apart from intracellular biological significance of S1P, the lipid exerts important functions by 
interacting with S1P receptors on the cell surface, of which 5 types exist, S1PR1–5 [9]. Through these 
receptors S1P can generate a plethora of signals via autocrine and/or paracrine signaling leading to 
various biological outcomes, such as cell survival, proliferation, differentiation, migration and 
immune responses. For example, local production and export of S1P can generate a concentration 
gradient between different compartments that can be chemotactic to subtypes of leukocytes, thereby 
stimulating their migration against the gradient of S1P (see also sections 2 and 3). Systemic transport 
of S1P with the blood flow occurs in complexed form bound to HDL or albumin (Figure 1A) [10,11]. 
In order to exert its extracellular functions, intracellularly generated S1P needs to be transported 
over the membrane by an active or passive transporter, since the molecule is too hydrophilic to simply 
diffuse over the membrane (Figure 1A). This is where ABC transporters come into play with the 
original discovery of ABCC1 as transporter for S1P in human and rodent mast cells [12] (Table S1). 
Release of S1P through ABCC1 was demonstrated pharmacologically, using the ABCC1 inhibitor 
MK571, and using a molecular approach involving downregulation of ABCC1 [12]. It is thought that 
S1P release regulates migration of mast cells towards antigen (see also section 3.3). S1P is released 
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Figure 1. S1P-centered metabolism, transport and its topology. A) In the plasma 
membrane sphingomyelin (SM) is sequentially converted to ceramide, sphingosine 
and sphingosine-1-phosphate (S1P) by sphingomyelinase (SMase), ceramidase 
(CDase) and sphingosine kinase (SphK1), respectively. SM is considered to localize 
in the exoplasmic leaflet and is not prone to flipping. SMase and CDase act on the 
exoplasmic leaflet, so sphingosine has to flip to the cytoplasmic leaflet of the plasma 
membrane, where SphK1 can act on it to produce S1P. S1P flops to the exoplasmic 
leaflet due to the action of ABC transporters, which have a lateral gate for 
lipids/lipophilic molecules in the plane of the membrane. Subsequently, S1P may be 
loaded onto APO proteins in the process of HDL particle formation. Alternatively, 
S1P is picked up from the cytoplasmic leaflet and directly loaded on the 
extracellular acceptor (HDL) by the ABC transporter. S1P outside the cell will be 
bound to HDL (or albumin) in equilibrium with a free pool of S1P and as such may 
generate a gradient from the blood circulation towards tissues with low S1P levels. 
Alternatively, S1P can be dephosphorylated to sphingosine by S1P phosphatases 
(SPP) or catabolized to hexadecanal and phosphoethanolamine by S1P lyase (SPL). 
B) After flopping to the exoplasmic leaflet, S1P can diffuse laterally and engage in 
binding to the lipid binding pocket of a S1P receptor (S1PR), which is located in the 
plane of the membrane, thus activating S1PR (autocrine signaling). Alternatively, 
extracellular S1P, be it soluble or HDL-bound, can travel to another cell, followed 
by incorporation into the exoplasmic plasma membrane of that cell, e.g. after 
binding of HDL to its receptor, SR-B1. There, S1P can similarly activate S1PR from 
within the membrane (paracrine signaling). 
constitutively from mast cells, but is enhanced by antigen stimulation, while both the constitutive and 
the stimulated release depend on ABCC1. In addition, antigen stimulation activates SphK and 
stimulates its translocation to the plasma membrane, thereby generating efficient production/export 
machinery together with ABCC1 at the plasma membrane (Figure 1A) [12]. The function of ABCC1 
as a S1P transporter was confirmed in several studies. ABCC1 was shown to export S1P in rat uterine 
leiomyoma ELT3 cells and late pregnant rat myometrium, since release is inhibited by MK571 or after  
downregulation by ABCC1 siRNA [13]. It was concluded that ABCC1 is involved in 4β-phorbol 
12,13-dibutyrate-induced COX2 expression mediated by SphK1/S1P which may contribute to 
leiomyoma growth. ABCC1 was also implicated in dexamethasone-mediated protection of human 
fibroblasts against (TNF-mediated) programmed cell death [14]. Both MK571 and ABCC1 siRNA 
abrogate the cytoprotective effect of dexamethasone, while ABCC1 siRNA treatment results in 
increased cellular S1P levels. Moreover, ABCC1 expression is upregulated by dexamethasone [14]. In 
murine blood-brain and blood-spinal cord barriers ABCC1 was identified as an important link between 
TNFα signaling and S1PR1-dependent reduction of ABCB1 activity [15]. Capillaries isolated from 
homozygous ABCC1-deficient mice do respond to S1P but not to TNFα in terms of reduced ABCB1 
activity, while MK571 inhibits sphingosine-mediated reduction of ABCB1 activity. This study places 
ABCC1 central in inside-out signaling via S1P export leading to S1PR1 activation and subsequent 
effects on ABCB1 [15]. 
187 
 
AIMS Molecular Science  Volume 1, Issue 4, 183-201. 
Apart from ABCC1, the ABC transporters ABCA1 and ABCG2 have also been implicated in S1P 
transport. In MCF7 human breast cancer cells estradiol stimulates S1P export from cells and this effect 
is suppressed by pharmacological inhibition or gene silencing of ABCC1 or ABCG2 [16] (Table S1). 
The secreted S1P may be involved in cancer progression and/or multidrug resistance of cancer cells. 
Retinoic acid/cAMP treatment of astrocytes induces extracellular S1P accumulation in HDL particles, 
which is inhibited by either ABCA1 siRNA treatment or the non-selective ABCA1 inhibitor 
glibenclamide [17] (Table S1). Moreover, astrocytes from Abca1 homozygous null mice display low 
S1P release in response to retinoic acid/cAMP treatment [17]. S1P release from human vascular 
endothelial cells is inhibited by MK571 as well as glibenclamide, suggesting involvement of ABCC1 
and ABCA1 [18]. However, plasma levels of S1P from Abca1, Abca7 or Abcc1 homozygous null mice 
do not show significant changes compared to wild-type mice [18]. This finding may indicate 
compensation by other transporters, for example SPNS2 (see also section 1.2). In this context, 
expression of functional ABCA1, ABCB1, ABCC1 or ABCG2 transporters in CHO/SphK1 cells does 
not lead to secretion of S1P in the medium of these cells, suggesting that ABC transporters alone are 
not sufficient to function as S1P transporters [19]. ABC transporters may need to interact with other 
proteins that could be absent in the CHO/SphK1 expression system. Alternatively, the lack of effect 
may be due to cell type specific modifications of ABC transporters in CHO cells.  
Given the potential role for blood and endothelial cells in establishing S1P gradients in the body, it 
is relevant to discuss the S1P transporters involved in these processes. Plasma and lymph have distinct 
sources that supply S1P and are maintained as separate compartments in this respect. High levels of 
S1P in plasma are generated by export of S1P from erythrocytes, platelets and endothelial cells, 
although the contribution of platelets appears to be small [11,20-25]. Erythrocytes are considered to be 
the major producer of plasma S1P (see also section 2). Lymphatic endothelial cells are likely the source 
of S1P in lymph [26]. Platelets appear to have two independent S1P transporters. One is 
ATP-dependent, stimulated by thrombin and inhibited by glibenclamide, but not MK571. This 
transporter was suggested to be ABCA1 and/or ABCA7 [27] (Table S1). The other transporter is 
stimulated by Ca2+ and not inhibited by glibenclamide [27]. In contrast to platelets, erythrocytes 
constitutively release S1P and do not depend on stimuli to release S1P. S1P release by erythrocytes is 
inhibited by glibenclamide [28]. Moreover, transport of S1P into rat erythrocyte inside-out membrane 
vesicles is also selectively inhibited by glibenclamide [28]. The effect of MK571 on blockade of S1P 
transport from erythrocytes, however, is conflicting. Previously, partial inhibition of S1P transport 
from erythrocytes by glibenclamide and MK571, either alone or combined, was demonstrated [29]. 
Taken together, the results suggest that S1P export from erythrocytes involves an ABCA subfamily 
member; ABCA7 is a more likely candidate than ABCA1, as the latter is not detectable in the 
erythrocyte vesicle preparation [28]. Involvement of ABCC1 needs to be further investigated. 
Interestingly, the uptake of S1P into erythrocyte inside-out membrane vesicles is supported not only by 
ATP, but also by dATP and AMP-PNP and not by ATPγS. This indicates a dependence of the 
transporter on adenine nucleotides with an intact γ-phosphate group, but no requirement for ATP 
hydrolysis [28]. 
Most of the studies on the involvement of ABC transporters in S1P export from cells rely on the 
use of pharmacological inhibitors, such as glibenclamide, which are not 100% specific [30] and thus 
may have off-target effects. Fortunately, in most cases the findings with pharmacological inhibitors are 
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validated with siRNA-knockdown in cell lines or gene targeting in mice. It should be noted that an 
alternative mechanism to generate extracellular S1P exists, that does not rely on export of 
intracellularly generated S1P. In this case the enzyme SphK1 is exported from vascular endothelial 
cells, is enzymatically active outside the cell and generates physiologically relevant amounts of S1P 
for S1PR stimulation. This mechanism may contribute to the establishment of the vascular S1P 
gradient [31,32]. 
Several models have been proposed for the mechanism of function of ABC transporters. 
Although ABC transporters were originally perceived as pore-forming proteins with an aqueous pore 
that acts as a channel allowing the movement of hydrophilic substrates across the membrane, it is now 
considered to function as a floppase, moving lipid soluble molecules from the inner to the outer plasma 
membrane leaflet. Combining this function with a potential loading function for substrates onto 
acceptors, provides the rationale for several models by which ABC proteins are perfectly fit for export 
of lipids, including S1P. As such they are now thought to be an essential link in S1P inside-out 
signaling. First, localization of S1P in the outer leaflet after flopping would be compatible with an 
autocrine function of the lipid by binding to a S1PR. Indeed, it is thought that S1P does not approach 
the receptor from the aqueous environment, but rather sideways in the plane of the membrane, 
consistent with the presence of an intramembranous lipid access channel in the receptor  
(Figure 1B) [33]. Second, for paracrine signaling functions S1P needs to be released into the aqueous 
environment. ABC transporters are considered to perform such a function by picking up the substrate 
(i.e. S1P) from the inner leaflet and loading it onto an acceptor molecule such as APO (in HDL) or 
albumin (Figure 1B). Third, S1P could be picked up from the outer leaflet and loaded on an 
extracellular acceptor (Figure 1B) [3]. 
1.2. SPNS2-mediated transport of S1P 
In 2008/2009, a novel S1P transporter,  SPNS2, was identified by two groups  
independently [34,35] (Table S1). Kawahara et al. investigated the features of the zebrafish ko157 
mutant [35]. A point mutation (R153S) in the gene encoding SPNS2 results in cardia bifida in 
zebrafish as a result of defective migration of myocardial precursors. This effect is likely mediated by 
the S1P/S1PR2 pathway, since the miles apart (mil)/S1PR2 mutant with a mutation in the gene 
encoding S1PR2 shows the same phenotype. Evidence is provided for an interaction between the genes 
coding for SPNS2 and S1PR2. Rescue experiments reveal that SPNS2 function is conserved from fish 
to mammals and suggest that SPNS2 functions upstream of S1PR2. Both zebrafish SPNS2-EGFP and 
human SPNS2-EGFP induce S1P export when expressed in CHO/SphK1 cells, in contrast to mutated 
variants [35]. FTY720 is a synthetic sphingosine analog that, after being phosphorylated, binds to and 
activates S1PR1, S1PR3, S1PR4 and S1PR5, but does not interact with S1PR2 [36]. Hisano et al. 
investigated the substrate specificity of human SPNS2 expressed in the CHO/SphK1 system and report 
that apart from S1P also FTY720, dihydro-S1P, and phyto-S1P are transported. This was the first 
identification of a transporter for FTY720 and shows that FTY720 uses the same transporter as  
S1P [19]. Dihydro-S1P transport by SPNS2 was confirmed in another study [37]. 
S1P transport was subsequently studied by various groups in Spns2-deficient mice, i.e. global or 
targeted disruption of Spns2 [37-41]. All studies agree that SPNS2 is important for S1P release from 
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endothelial cells, which in two studies is demonstrated using endothelial-specific knockouts of  
Spns2 [38,40]. SPNS2 is not involved in S1P release from erythrocytes [38,39] or platelets [39]. The 
murine studies further demonstrate that knock out of Spns2 results in a different phenotype from 
zebrafish. Zebrafish present with a prominent cardiovascular phenotype while mice lack 
developmental defects but show a prominent lymphocyte trafficking phenotype. This indicates 
divergence in expression and/or functions of SPNS2 between these species and could mean potential 
divergence in humans as well. SPNS2 may well be involved in many other cell types and processes. 
Recently it was shown that SPNS2 is expressed in murine osteoblastic MC3T3 cells and its 
downregulation by siRNA treatment results in impaired paracrine signaling towards prostate cancer 
cells, which are supported by S1P in terms of proliferation and survival [42]. 
The molecular structure of SPNS2 is unknown and awaits crystallization of the protein and 
high-resolution structure determination. Based on the predicted amino acid sequence, it belongs to the 
major facilitator superfamily (MFS) of transporters [10]. These V-shaped transporters have 12 
transmembrane helices and recognize hydrophilic substrates. As discussed, S1P is lipophilic and likely 
approaches membrane proteins laterally in the plane of the membrane, as is the case for ABC 
transporters and S1PR1 (Figure 1B). The shape of MFS transporters could be compatible with such a 
function, as it shows similarities with the V-shaped ABC transporters with 12 transmembrane helices. 
It can be speculated that SPNS2 similar to ABC transporters has a lateral substrate access gate in the 
plane of the membrane. 
In conclusion, various members of the ABC transporter family on the one hand and SPNS2 on the 
other hand have so far been identified as S1P transporters. For ABCC1 this has been established in 
various cell systems. Members of the ABCA subfamily are implicated as well, but this needs further 
confirmation, especially regarding ABCA7. Given their expression on blood and endothelial cells and 
the inducible expression of S1PRs in leukocytes, S1P transporters play an important role in leukocyte 
trafficking, as will be discussed below. 
2. Involvement of S1P in lymphocyte trafficking 
Release of matured T cells and immature B cells from thymus and bone marrow, respectively, 
appears to be regulated by SPNS2. Mice deficient for Spns2 in endothelial cells have a reduced egress 
of T cells from the thymus and B cells from the bone marrow [38]. Upon maturation, T cells upregulate 
the expression of S1PR1 and migrate from the thymus into the circulation, stimulated by the gradient of 
S1P produced by neural crest-derived pericytes (Figure 2A) [43]. As a consequence, mice systemically 
deficient for Sphk1 or lacking Spns2 in endothelial cells not only have a reduced number of circulating 
lymphocytes, but also a lower number of lymphocytes in secondary lymphoid organs [26,38]. 
However, although circumstantial evidence might suggest a role for SPNS2 in transporting S1P from 
thymic pericytes, no direct data is available yet to support this hypothesis. Cross-breeding 
Spns2-floxed mice with Wnt1-Cre mice will lead to specific deletion of Spns2 in thymic pericytes and 
may provide direct evidence for the role of SPNS2 in release of S1P from these cells. Taken together, 
the available data suggest that SPNS2 plays an important role in regulating the release of T and B cells 
from primary lymphoid organs into the circulation. 
Recirculation of (mature) lymphocytes is essential for proper adaptive immune function by  
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Figure 2. Effects of S1P on leukocyte migration. A) Upon maturation in primary 
lymphoid organs, T cells (thymus), B cells and mast cells (both in bone marrow) 
upregulate the expression of S1PR1. The gradient of S1P, with relatively high levels in 
the plasma generated from transport of S1P from thymic pericytes (potentially by 
SPNS2), stimulates egress of cells into the circulation. In contrast to primary 
lymphoid organs, it is not clear whether it is the S1P gradient (relatively high levels of 
S1P in plasma) or the absolute level of S1P that stimulates egress from secondary 
lymphoid organs (lymph nodes and spleen). S1P is transported by SPNS2 from 
endothelial cells to the lymph and subsequently stimulates egress of lymphocytes and 
mast cells from secondary lymphoid organs through S1PR1 signaling (not shown). 
Levels of S1P in plasma are mainly regulated by erythrocytes and vascular 
endothelial cells. Erythrocytes presumably use ABCA7 while endothelial cells use 
SPNS2 to transport S1P. B) An inflammatory stimulus increases the tissue S1P level 
(potentially produced by mast cells) and subsequently increases the migration of 
macrophages, neutrophils and mast cells to the inflammatory site. 
allowing immune surveillance and the induction of an immune response by interaction with other 
leukocytes. Therefore, T and B cells recirculate by entering lymph nodes through high endothelial 
venules (HEVs) and leave the lymph nodes on the abluminal side into the efferent lymphatics [36]. In 
turn, the lymphocytes migrate back to the blood through the efferent lymphatics that eventually drain 
into the thoracic duct [44]. S1P is suggested to play an essential role in stimulating egress of 
lymphocytes from secondary lymphoid organs, as demonstrated by experimental internalization of 
S1PR1 by FTY720. Injection of FTY720 leads to a significant lymphopenia after 4 hours (93% 
decrease in CD4+ and 88% decrease in CD8+ T cells; 90% decrease in B cells), without affecting the 
number of myelomonocytic cells in blood, as demonstrated in mice and rats [45,46]. FTY720 not only 
leads to a reduced number of lymphocytes in blood, but also in the thoracic duct [36,45], suggesting 
sequestration of lymphocytes within secondary lymphoid organs. Moreover, within lymph nodes 
FTY720 induces migration of lymphocytes from the sinuses towards the lymph node exit sites, the 
abluminal side of the endothelial layer [36]. Likely, loss of S1P-sensing due to internalization of the 
S1P receptor by FTY720 induces retention of lymphocytes in lymph nodes, lowering the number of 
lymphocytes in blood. In addition, it was demonstrated that a reduction in the plasma level of S1P 
leads to lymphopenia as well. During mammalian hibernation, S1P plasma levels are reduced due to a 
reduced release of S1P from erythrocytes and this leads to a 95% decrease in the number of circulating 
lymphocytes [29]. Studies using knockout mice suggest that S1P signaling through S1PR1 is essential 
for migration of lymphocytes from secondary lymphoid organs back into the systemic circulation 
(Figure 2A) [1,2,26]. Thus, signaling of S1P through S1PR1 on lymphocytes seems to play an essential 
role in stimulating release of lymphocytes into the circulation. 
Recirculation of lymphocytes through blood and secondary lymphoid organs is suggested to 
primarily depend on S1P, although the exact mechanisms remain to be unraveled. As such, one 
hypothesis is that lymphocyte egress depends on a S1P gradient between blood and lymph, with high 
levels in blood and low levels in lymph (Figure 2A) [1,26]. Erythrocytes are considered to be an 
important source of plasma S1P since they do not possess S1P-degrading enzymes and display a high 
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SphK activity [26,47,48]. Transplantation of Sphk-deficient bone marrow from mice deficient for both 
Sphk1 and Sphk2 into wild-type mice leads to a 10-fold reduced S1P plasma level, while 
transplantation of Sphk1+/−Sphk2−/− bone marrow to irradiated wild-type mice does not affect the S1P 
plasma level [26]. Hence, these data show that SphK1 in erythrocytes seems to be responsible for up to 
90% of S1P in plasma. In addition to a role for SphK1 in erythrocytes, experimental ablation of Spns2 
demonstrates a role for SPNS2 in endothelial cells in regulating S1P in plasma. Knockout of Spns2 
completely abolishes the S1P transport from vascular endothelial cells and leads to a 40–50% 
reduction in the S1P plasma level [37,39,40]. Moreover, expression of SPNS2 is barely detectable in 
bone marrow and Spns2-deficiency in mice does not affect release of S1P from erythrocytes [39]. 
Taken together, these results indicate that 50–90% of plasma S1P is derived from erythrocytes 
produced by SphK1 and is not transported by SPNS2, while 10–50% of plasma S1P is likely produced 
by SphK2 and released from endothelial cells by SPNS2. 
Although transplantation of Sphk-deficient bone marrow into wild-type mice leads to a lowered 
S1P plasma level, the level of S1P in lymph is not affected [26]. As a consequence of the lowered S1P 
level in plasma, the S1P gradient between plasma and lymph is disrupted. However, the number of 
lymphocytes in thymus, secondary lymph nodes and blood is not different from control mice [26]. 
Hence, although it is hypothesized that lymphocyte egress depends on a S1P gradient between blood 
and lymph, current data reveal that this gradient is unlikely to be the sole factor driving lymphocyte 
egress [26,49,50]. Since Sphk1-deficient mice have a reduced S1P plasma level but no significant 
reduction in the number of circulating lymphocytes [26,50], local production and release of S1P in 
lymphoid organs seem to be the key factors in regulating lymphocyte recirculation. In addition to 
promoting release of lymphocytes from thymus and bone marrow (primary lymphoid organs) as 
described above, SPNS2 also seems to play an important role in regulating local levels of S1P in lymph 
and thereby stimulating lymphocyte egress from secondary lymphoid organs. Intriguingly, 
contradicting findings on lymph S1P levels are reported in Spns2-deficient mice. Mendoza et al. 
demonstrated that specific knockout of Spns2 in endothelial cells leads to a reduced S1P level in 
plasma and lymph [40]. Nagahashi et al. on the other hand revealed that mice systemically deficient for 
Spns2 have decreased levels of S1P in plasma, while the level of S1P in lymph is increased [37]. It 
should be noted however, that both Mendoza et al. and Nagahashi et al. used a mouse model that 
lacked Spns2 in all endothelial cells, not specifically in lymphatic endothelial cells. Cross-breeding 
Spns2-floxed mice with Lyve1-Cre mice would lead to specific knockdown of Spns2 in lymphatic 
endothelium. To our knowledge, no study thus far used such an approach to demonstrate the specific 
role of SPNS2 in transporting S1P from lymphatic endothelium. As described above, export of SphK 
may lead to the production of physiological amounts of extracellular S1P and thus may contribute to 
the formation of a S1P-gradient in addition to transport of S1P from cells [31,32]. Hence, in addition to 
transport of S1P from endothelial cells by SPNS2, extracellular SphK might well contribute to local 
formation of S1P in lymph. 
Despite different effects on the S1P level in lymph, both systemic and endothelial-cell specific 
knockout of Spns2 in mice leads to a reduced number of circulating lymphocytes. In addition, 
Spns2-deficient mice have increased numbers of T cells in thymus, especially CD4+ CD62L+ CD69− 
and CD8+ CD62L+ CD69−, which represent matured T cells [37]. Therefore, the increased number of 
T cells in thymus from Spns2 deficient mice is likely due to diminished release of these cells from the 
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thymus rather than secondary to overproduction of T cells, which is in line with previous studies 
demonstrating the essential role for SPNS2 in stimulating egress of lymphocytes from thymus and 
bone marrow [38]. Hence, it seems likely that lymphopenia in Spns2-deficient mice is secondary to 
inhibition of thymic egress. However, experimental ablation of the S1P-gradient between thymus and 
plasma by knockout of Lipid phosphate phosphatase 3 in thymic epithelial cells or Sphk in neural 
crest-derived thymic pericytes in mice, leads to similar levels of T cell accumulation in the thymus, but 
only a slight reduction in the number of T cells in blood as compared to Spns2-deficient mice [43,51]. 
In contrast, knockout of Sphk in lymphatic endothelial cells does not affect thymic lymphocyte egress, 
but leads to a similar reduction in the number of circulating lymphocytes as compared to mice deficient 
for Spns2 [43,52].Therefore, the reduced number of lymphocytes in blood in Spns2−/− mice is likely 
due to a combination of reduced egress from primary and secondary lymphoid organs, i.e. thymus and 
lymph nodes. 
Taken together, it is clear that SPNS2 plays an essential role in stimulating egress of lymphocytes 
from primary lymphoid organs and regulates S1P in lymph by transporting S1P from endothelial cells. 
Although the precise effects of S1P on lymphocytes remain to be unraveled, mounting evidence 
suggests a major role for S1P signaling through S1PR1 in regulating lymphocyte egress from 
secondary lymphoid organs. 
3. Role of S1P in regulating migration and function of other leukocytes 
Besides the effects of S1P signaling on lymphocytes there are effects on innate immune cell 
trafficking. The innate immune system usually responds quickly to an inflammatory stimulus with the 
infiltration of phagocytes such as neutrophils, macrophages and dendritic cells [53]. Adhesion 
molecules on the endothelial surface are upregulated in response to a pathogen, either directly via 
binding of the pathogen to an endothelial pattern-recognition receptor (PRR) or indirectly via tissue 
resident leukocytes that release inflammatory mediators (such as histamine and cytokines) [54]. The 
leukocyte-endothelial interaction leads to leukocyte influx at the inflammatory site and this involves a 
number of processes, including rolling, adhesion, and transmigration. 
Although S1P has been shown to influence a range of cells and functions from the innate immune 
system most studies used pharmacological compounds, while the use of siRNA-knockdown in cell 
lines or gene targeting in mice has been limited. Additionally, research has focused on the role of 
receptors and kinases, while the investigation of the role of S1P transporters has been mostly neglected. 
Here, we summarize the current knowledge about S1P involvement in leukocytes other than 
lymphocytes. 
3.1. Neutrophils 
Neutrophils are among the first leukocytes to be recruited at the inflammatory site where they 
eliminate pathogens by phagocytosis, degranulation or neutrophil extracellular traps (NETs) [54]. An 
inflammatory challenge such as the injection of carrageenan (a polysaccharide) increases S1P locally 
and it declines when inflammation resolves [55]. It is suggested the S1P is transported from the blood 
into the inflamed tissue. Alternatively, mast cells that are also recruited during an inflammatory 
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response might contribute to the local S1P increase as hypothesized by Olivera et al. [56] since mast 
cells can release S1P via ABCC1 (see also sections 1.1 and 3.3; Figure 2B) [12]. Injection of 
carrageenan leads to neutrophil infiltration and local edema in rats, which can be completely precluded 
by neutralization of S1P by LT1002 (a monoclonal antibody against S1P) as well as blockage of the 
S1PR1 by W123 (a S1PR1 antagonist) [57]. S1P increases adhesion of human neutrophils to 
endothelium coated with suboptimal immune complex density in vitro [58], while injection of FTY720 
reduces neutrophil rolling [59]. However, S1PR modulation by either FTY720 (effects on S1PR1, 
S1PR3, S1PR4 and S1PR5) or BAF312 (effects on S1PR1 and S1PR5) does not affect the number of 
neutrophils in blood [60]. Thus, neutrophil circulation seems to be independent of S1P receptors, while 
neutrophil infiltration depends on S1P binding via S1PR1. Likely, reduced influx of neutrophils into 
tissues is secondary to inhibition of rolling and adhesion of neutrophils to the vascular endothelium. 
Histamine-induced neutrophil rolling can be reduced by inhibiting sphingosine kinases and is 
also reduced in Sphk1−/− mice, but not in Sphk2−/− mice [59]. In contrast to these findings, Zemann et 
al. reported no differences in neutrophil circulation or function in a study with knockout mice for 
Sphk1 or Sphk2 [61]. They observed normal calcium-influx as well as normal in vitro migration after 
different stimuli. Moreover, recruitment of neutrophils into the peritoneum (following injection of the 
neutrophil chemokines KC and MIP-2) and peripheral blood (following injection of the chemotactic 
peptide fMLP) in vivo were normal. Thus although knockout of Sphk1 reduces neutrophil rolling, 
eventual neutrophil recruitment seems independent from sphingosine kinases. Further, the number and 
function of neutrophils in blood does not appear to be mediated by the absolute S1P level in plasma, 
which is different in the two different knockout models. While Sphk1−/− mice have a reduced plasma 
level S1P due to lower S1P production (see also section 2), data on the S1P plasma level in Sphk2−/− 
mice are conflicting. Linke et al. show that the measured S1P plasma levels depend on centrifugation 
speed, which suggests release from damaged cells upon centrifugation [62]. When taking the 
centrifugation speed into account, the S1P plasma levels in Sphk1−/− or Sphk2−/− mice were not 
different from the S1P plasma level in wild-type mice, although the intracellular S1P level is increased 
in Sphk2−/− mice. Hence, the reported increased level of S1P in plasma from Sphk2−/− mice seems to 
represent a technical artefact, due to release from damaged erythrocytes. The higher level of S1P in 
erythrocytes might be due to a compensatory elevation of SphK1 [56,63]. 
The apparent contradictions between the study of Zemann et al. and other studies might be 
explained by a difference in tissue S1P concentration, since S1P concentrations were influenced 
locally in tissue in the three studies that document alterations in neutrophil function [57,58,59]. In 
healthy tissue S1P gradients are short-lived due to degradation of S1P by S1P lyase [64]. However, 
inhibition of S1P breakdown or increased release of S1P can stabilize the gradient and influence the 
local inflammatory response. Taken together, is it likely not the absolute S1P levels, but rather the 
relative S1P gradient between different compartments, such as blood and tissue, which stimulates 
migration and activation of neutrophils (Figure 2B). In line with this notion, Allende et al. revealed that 
S1p lyase deficient (Sgpl1−/−) mice with permanently elevated levels of circulating S1P and increased 
S1P levels in tissues have neutrophilia as well as impairment of neutrophil function, including inability 
to migrate into tissues [65]. Thus, neutrophil migration and function seem to be mediated by local 
levels of S1P in tissues. Unfortunately the source of increased tissue S1P during inflammation has not 
been explored, although it might be a good target for specific immunomodulation. 
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3.2. Monocytes, macrophages and dendritic cells 
As for neutrophils, research on monocytes, macrophages and dendritic cells has primarily 
focused on the role of S1P receptors, while the role of S1P transporters is still unclear. Monocytes can 
migrate into tissues and differentiate on demand into macrophages and dendritic cells [53]. Immature 
dendritic cells (DCs) are present in nearly all kinds of tissue as highly efficient antigen presenting  
cells [66]. DCs continuously migrate from the periphery to lymph nodes, where they interact with T 
cells. 
S1PR modulators (FTY720 and BAF312) under normal and inflammatory conditions restrict 
egress of monocytes from hematopoietic organs (spleen, bone marrow) and thereby reduce the number 
of circulating monocytes [60,67]. These findings resemble the effects of FTY720 on lymphocytes (see 
also section 2). In contrast to lymphocytes and monocytes, DCs are retained in blood and depleted in 
hematopoietic organs upon administration of FTY720 in mice. Moreover, FTY720 decreases 
expression of DC-adhesion molecules and impairs chemotactic responses [68]. The impaired 
migration of immature DCs from blood towards the spleen could result in spleen DC depletion since 
these cells have a short half-life. On the other hand, the S1PR1 agonist SEW2871 increases the number 
of DC in the blood as well, but only for a limited time (< 24 hours) and without depleting DCs in 
hematopoietic organs. It is hypothesized that the difference in effects of FTY720 and SEW2871 is due 
to downregulation of S1PR1 by FTY720-induced S1PR1 internalization and degradation. Thus, 
stimulation of S1PR1 seems to increase recirculation of DCs through an initial increase in the number 
of circulating DCs in blood. 
In vitro S1P is chemotactic for immature, but not mature human DCs [69]. In contrast to human 
DCs, murine DCs upregulate the expression of S1PR1 and S1PR3 upon maturation. This leads to 
increased sensitivity for and migration towards S1P in mature DCs [70]. Although it cannot be 
excluded that the differential effect of S1P on mature DCs is due to technical differences, this is likely 
due to differences in species or in the source of the cells (blood versus bone marrow). 
3.3. Mast cells 
Mast cells are early sentinels of immune activation that have a role in fine-tuning of the immune 
response through release of pro- as well as anti-inflammatory substances [71]. A range of mast cell 
functions are regulated by S1P signaling, as reviewed in detail by Olivera et al. [56]. Stimulation of 
mast cells by allergens and IgE results in SphK1 activation and subsequent S1P production [72,73]. 
SphK1 is involved in anaphylaxis through the production of intracellular S1P by mast cells as well as 
production of circulating S1P from other sources, such as endothelial cells and platelets [73]. 
Intracellularly produced S1P can be exported from mast cells by ABCC1 (see also section 1.1) [12]. 
However, mast cells are not major contributors to the maintenance of a S1P gradient in the blood, since 
mast cell deficient mice (W−sh/W−sh) do not have altered S1P levels in the blood, while reconstitution of 
mast cells in these mice has no effect on the blood S1P concentration either [73]. 
Inhibition of the SphK1 completely prevents migration of mast cells towards antigen, while 
preserving their ability to migrate to S1P [72]. This suggests the migration of mast cells towards 
antigen depends on the production of S1P via SphK1 (Figure 2B). Interestingly, knockout of Sphk1 in 
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mice leads to lower circulating S1P and resistance to anaphylaxis, a process in which mast cells have 
an important role [73]. However, Sphk2−/− mice did develop anaphylaxis. The different anaphylactic 
responses in these two mice strains may depend on the plasma level of S1P, possibly being low in 
Sphk1−/− mice, but high in Sphk2−/− mice (see also section 3.1) [63,73]. It has been suggested that the 
increased plasma S1P level in Sphk2−/− mice results in quick recovery from anaphylaxis and fast 
clearance of the histamine (one of the inflammatory mediators released by mast cells) [73]. High S1P 
promotes vasculature integrity and increases blood pressure through S1P receptors and thereby 
increases histamine clearance and attenuates anaphylaxis. The differential effects of Sphk1−/− and 
Sphk2−/− on mast cell function and anaphylaxis illustrates the redundancy in S1P-signaling, with 
contrary responses to locally versus systemically produced S1P, which hampers the discovery of novel 
pharmaceutical targets for resolution of inflammatory responses such as anaphylaxis. Thus, mast cell 
activity seems to depend on sphingosine kinases, although it remains to be unravelled whether this is 
mediated by the plasma S1P level, intracellular production of S1P in mast cells or both. 
Extracellular S1P transactivates S1PR1 and/or S1PR2 [72]. The S1PR2, but not the S1PR1 is 
upregulated after FcԑRI cross-linking. S1PR1 activation leads to migration of mast cells towards 
antigen, while activation of S1PR2 induces degranulation and inhibits mast cell motility (Figure 2B). 
These supplementary effects optimize mast cell function: S1PR1 activation leads to mast cell migration 
towards antigen, whereas at the inflammatory site upregulation of S1PR2 by antigen leads to cessation 
of migration and site-specific degranulation [72,74]. 
In conclusion, S1P seems to be involved in a wide range of leukocyte functions, including 
migration towards an inflammatory site. However, it is still not precisely clear whether the plasma 
level of S1P or local levels of S1P (i.e. in tissue or secondary lymphoid organs) are the primary 
determinants for functional modulation of different subtypes of leukocytes. Further research may 
enlighten the complex interactions between different immune cells in S1P-dependent signaling and 
elicit new targets for immunomodulation. 
4. Conclusion 
So far members of two families of proteins are known to function as S1P transporters, i.e. ABC 
transporters and SPNS2. A recurrent theme in literature is that disruption of a certain S1P transporter 
leads to incomplete inhibition of S1P release, indicating redundancy through compensation by other 
transporters. Moreover, the exact nature of the S1P transporter in erythrocytes and platelets remains 
elusive, although it shows characteristics of ABC transporters. In view of these notions, it is likely that 
additional S1P transporters will be identified in future research. These could include other ABC 
transporter family members, other members of the MSF (although SPNS1 appears to be excluded [35]), 
but it would not be surprising if entirely novel S1P transporters will be identified. The S1P transporters 
have an important role in establishing S1P gradients in the body that are important for immune system 
function. This includes the regulation of leukocyte migration and function in the conditions of 
homeostasis as well as inflammation. However, it remains to be clarified whether the absolute level of 
S1P in plasma or the local production of S1P resulting in a S1P gradient between different 
compartments is the primary determinant and how this affects different subtypes of leukocytes. 
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Table summarizes the known transporters for S1P, where they are localized and in which function they play a role, with 
references to the literature. 
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